Neurocrine Biosciences Inc. filings document the regulatory record of a commercial biopharmaceutical company developing and selling treatments for neurological, psychiatric, endocrine and immunological disorders. Its 8-K reports cover operating and financial results, product-sales disclosures, clinical or regulatory updates, material agreements, capital-structure matters and executive or employment-related governance events.
Proxy filings describe board matters, shareholder voting items, executive compensation, equity awards and pay-versus-performance disclosures. The filing record also includes formal disclosures related to INGREZZA, CRENESSITY and the company's pipeline, as well as risk, governance and transaction-related disclosure categories relevant to its public-company status.
Neurocrine Biosciences, Inc. (NBIX) reported insider equity activity by Chief Corp. Affairs Officer David W. Boyer. On September 11, 2026, 3,587 shares of common stock were acquired at no cost upon vesting of previously granted performance restricted stock units after a performance metric was certified. On the same date, 1,936 shares were withheld by the company to satisfy tax withholding requirements on the PRSU vesting, and no shares were sold in that transaction. On September 14, 2026, 826 shares were sold in the open market at a weighted average price of $157.4462 per share under a Rule 10b5-1 trading plan adopted on February 23, 2026.
Neurocrine Biosciences Inc. (NBIX) reported that Chief Commercial Officer Eric Benevich received a grant/award acquisition of 6,275 shares of common stock on September 11, 2026 upon certification of a performance metric under previously granted PRSUs. On the same date, the company withheld 3,386 shares at $156.22 per share to satisfy tax withholding requirements on the vesting; the filing states that no shares were sold and no Rule 10b5-1 trading plan is reported.
Neurocrine Biosciences Inc (NBIX) Chief Financial Officer Matt Abernethy reported a mix of equity award vesting, tax withholding, and open-market sales. On September 11, 2026, 5,020 shares of common stock were acquired upon vesting of performance restricted stock units after a performance metric was certified; on the same date, 2,709 shares were withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements, with no shares sold in that transaction. On September 14, 2026, he sold 2,311 shares of common stock in transactions effected by a broker at a weighted average price of $157.1981 per share, under a Rule 10b5-1 trading plan, with individual sale prices ranging from $157.05 to $157.43 per share.
NEUROCRINE BIOSCIENCES INC (NBIX) has a notice on file under Rule 144 for a potential sale of its common stock by officer Matthew C. Abernethy. The filing covers 2,311 shares of common stock, with an aggregate market value of $361,024.42, and references an intended sale date of September 14, 2026 on NASDAQ. The shares are tied to Performance Stock Units that were acquired from the issuer.
NEUROCRINE BIOSCIENCES INC (NBIX) received a Rule 144 notice from officer David Warren Boyer covering the planned sale of 4,714 shares of common stock through Morgan Stanley Smith Barney. The shares were or will be acquired upon vesting of restricted and performance stock units during the period from January 31, 2026 through September 14, 2026.
NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Commercial Officer Eric Benevich exercised employee stock options and sold a portion of the resulting shares. On September 9, 2026, he exercised options for 3,194 shares of common stock at an exercise price of $43.24 per share, and on the same date sold 2,154 shares of common stock at $154.61 per share. The options had been granted on February 6, 2017 and were scheduled to expire on February 6, 2027. The sale was effected by a broker under a Rule 10b5-1 trading plan adopted by Mr. Benevich on June 10, 2026, and company policy restricts him from amending such plans after adoption. A separate footnote states that his reported holdings include 178 shares acquired through the company’s 2018 Employee Stock Purchase Plan.
NEUROCRINE BIOSCIENCES, INC. (NBIX) received a Rule 144 notice that officer Eric Benevich plans to sell up to 2,154 shares of common stock. The shares are expected to be sold on or about September 9, 2026 on NASDAQ through Morgan Stanley Smith Barney LLC after a cash exercise of stock options.
NEUROCRINE BIOSCIENCES INC (NBIX) director Stephen A. Sherwin reported a disposition of company shares through a bona fide gift of 1,000 shares of Common Stock effective September 2, 2026. According to the filing, this was a gift/charitable contribution, not a market transaction, and no value was received for the shares.
Following this charitable transfer, Sherwin directly holds 14,860 shares of Neurocrine Biosciences Common Stock. No Rule 10b5-1 trading plan is reported in connection with this transaction.
NEUROCRINE BIOSCIENCES INC Chief Scientific Officer Jude Onyia reported a bona fide gift of 2,409 shares of common stock effective August 4, 2026. No value was received and it was not a market transaction. Following the gift, Onyia directly holds 20,996 shares of common stock.
Neurocrine Biosciences, Inc. filed an amendment to a prior current report to add full financial detail for its completed acquisition of Soleno Therapeutics. The update includes Soleno’s audited 2025 results, unaudited first‑quarter 2026 results, and unaudited pro forma condensed combined statements of income prepared under Article 11 of Regulation S‑X.
On a pro forma basis, combined revenues were $1,907.5 million for the six months ended June 30 2026 and $3,050.9 million for 2025, with pro forma net income of $294.0 million and $324.5 million, respectively. The acquisition adds VYKAT XR, valued at an estimated $2,237.8 million as an identifiable intangible asset with a 16‑year life, driving significant new amortization expense. Neurocrine also highlights a five‑year $1.0 billion senior secured revolving credit facility, from which it drew and fully repaid $600.0 million shortly after closing.